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Background: Certain antidepressant drugs namely Sertraline hydrochloride, Fluoxetine hydrochloride, Paroxetine
hydrochloride, Thioridazine hydrochloride and Amineptine hydrochloride were studied throughout this work using
spectrofluorimetric method.
Methods: The spectrofluorimetric method is based on the charge-transfer reaction of these drugs as n-electron
donors with 7,7,8,8-tetracyanoquinodimethane (TCNQ) as π-electron acceptor. The drug-TCNQ complexes showed
excitation maxima ranged from 290-301 nm and emission maxima ranged from 443-460 nm.
Results and discussion: The different experimental parameters affecting the formation and stability of the
complexes were carefully studied and optimized. The calibration plots were constructed over the range of 50-450
ng mL-1 for Fluoxetine and Sertraline, 50-550 ng mL-1 for Paroxetine, 50-650 ng mL-1 for Thioridazine and 50-750
ng mL-1 for Amineptine. The proposed method was validated according to ICH and USP guidelines with respect to
specificity, linearity, accuracy, precision and robustness.
Conclusion: A simple, reliable, sensitive and selective spectrofluorimetric method has been developed for
determination of certain antidepressant. The proposed method was successfully applied to the analysis of the cited
drugs in dosage forms. The high sensitivity of the proposed method allows determination of investigated drugs in
spiked and real human plasma.
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Spectrofluorimetric determinationBackground
Depression: a common mental disorder is a chronic
or recurrent illness that affects both economic and
social functions of patients and can eventually lead
to suicidal behaviors. Antidepressant medications
have been used to treat all forms of major depressive
disorders (Parfitt & Martindale 2002). In the last
years prescription of antidepressants has increased
dramatically in Egypt. Sertraline, paroxetine, fluoxet-
ine and amineptine are extensively used as anti-
depressant drugs in Egypt while thioridazine is a
potent antipsychotic agent which is used in treat-
ment of depression accompanied with anxiety. The
chemical structures of the studied drugs in this work* Correspondence: momar1971g@yahoo.com
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in any medium, provided the original work is pare shown in Table 1. Several methods have been
published for determination of these drugs in bulk
or in different pharmaceutical formulations as well
as in biological fluids. These methods include Volu-
metric methods (Bueno et al. 2000; Delazzeri 2005;
Basavaiah et al. 1999), Spectroscopic methods (Onal
et al. 2005; Darwish & Refaat 2006; Patel et al. 2009;
Darwish 2005; Mohamed et al. 2005; Mohamed et al.
2007), Electrochemical methods (Nouws et al. 2006;
Atta-Politou et al. 2001), Chromatographic methods
(Zainaghi et al. 2003; Nevado et al. 2006; Meiling
et al. 2002; Sbarra et al. 1979, 1981; Tsaconas et al.
1989) and Capillary electrophoretic methods (Labat
et al. 2002; Mandrioli et al. 2002).
The wide use of these drugs necessitates the devel-
opment of simple, accurate, sensitive, applicable and
cheaper method for their determination in pure
forms, pharmaceutical formulations, spiked and realOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Structural formula of the studied drugs
Name Chemical name Structure
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very sensitive spectrofluorimetric method for deter-




– A perkin Elmer LS 45 Luminescence spectrometer
(United Kingdom) connected to an IBM PC
computer loaded with FL WINLABTM software.
– SpectronicTM GenesysTM 2PC. Ultraviolet/Visible
spectrophotometer (Milton Roy Co, USA) withmatched 1 cm quartz cell connected to IBM
computer loaded with winspecTM application
software.
– Milwakee SM 101 pH meter (Portugal).
– Digital analytical balance (AG 29, Meltter Toledo,
Glattbrugg, Switzerland).
– Laboratory centrifuge 4000 rpm (Bremsen ECCO,
Germany).
Materials and reagents
All materials were of analytical reagent grades and the so-
lutions were prepared with double distilled water. Samples
of investigated drugs were generously supplied by their
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purification; Sertraline hydrochloride was kindly provided
by Pfizer Egypt, S.A.E., Cairo, Egypt. Fluoxetine hydro-
chloride was kindly provided by EIPICO, El Asher
Ramadan City, Cairo, Egypt. Paroxetine hydrochloride
was kindly provided by Pharaonia Pharmaceuticals Pharo
Pharma, Alexandria, Egypt. Amineptine hydrochloride
was kindly provided by Servier Egypt Industries Limited,
6th October City, Giza, Egypt and thioridazine hydro-
chloride was supplied by Delta Pharm, S.A.E, El Asher
Ramadan City, Cairo, Egypt.
7,7,8,8-tetracyanoquinodimethane (TCNQ) (Sigma Che-
mical Co., USA) was prepared as 1 × 10-3 M in aceto-
nitrile. Solution was found to be stable for at least one
week at 4°C. Acetonitrile, diethyl ether and methanol
(Riendel-De-Haen AG, Germany). Chloroform, 1, 2
Dichloromethane, Ethanol and 33% W/V ammonia solu-
tion (El Nasr chemical Co., Abu Zabbal, Egypt).
Plasma was kindly provided by EL-Minia Hospital of
Psychiatric medicine and kept frozen until assay.
Pharmaceutical formulations
The following available commercial preparations were
analyzed; LustralW tablets (Pfizer Egypt, S.A.E., Cairo,
Egypt) labeled to contain 50 mg sertraline per tablet.
FlutinW capsules (EIPICO, El Asher Ramadan City,
Cairo, Egypt) labeled to contain 20 mg Fluoxetine per
capsule. PaxetinW tablets (Pharaonia Pharmaceuticals
Pharo Pharma, Alexandria, Egypt) labeled to contain
20.0 mg of paroxetine per tablet. SurvectorW tablets
(Servier Egypt Industrial Limited, 6th October City,
Giza, Egypt) labeled to contain 100.0 mg of Amineptine
hydrochloride per tablet. ThiozineW tablets (Delta Pharm,
S.A.E, El Asher Ramadan City, Cairo, Egypt) labeled to
contain 100 mg of Thioridazine hydrochloride per tablet.
Preparation of standard solutions
An accurately weighed 20.0 mg salt of each investigated
drugs, was transferred into 125-mL separating funnel
containing about 20 mL of distilled water. The resultant
solution was rendered distinctly alkaline with dropwise
addition of 33% w/v aqueous ammonia solution. The
librated free base was extracted with three potions of
5 mL chloroform. The combined chloroformic extracts
were filtered through anhydrous sodium sulfate sup-
ported on Whitman filter paper. The filter paper was
washed thoroughly with two portions of 5 mL chloro-
form. The combined extracts and washings were diluted
to volume with chloroform to provide a stock standard
solution containing 200.0 μg mL-1. This solution was
further diluted with the same solvent to prepare working
standard solutions containing 0.50 - 4.50 μg mL-1 of flu-
oxetine and sertraline, 0.50- 5.5 μg mL-1 of paroxetine,
1.0-6.5 μg mL-1 of thioridazine and 1.0-7.5 μg mL-1 ofamineptine. The standard solutions were stable for seven
days when kept in the refrigerator.
General analytical procedure
Into a series of 10 mL volumetric flasks, 1.0 mL of work-
ing standard solution of each drug was transferred over
the cited concentration. One mL of 1 × 10-3 M TCNQ
solution was added and mixed well. The reaction mix-
ture was allowed to stand at room temperature (25.0 ±
5°C) for 40 min for fluoxetine, sertraline and paroxetine;
35 min for thioridazine and 45 min for amineptine then
completed to the mark with chloroform. The fluores-
cence intensity of the complexes was measured at 443,
447, 447, 450 and 458 nm after excitation at 290, 291,
291, 295 and 301 nm for fluoxetine, sertraline, paroxe-
tine, amineptine and thioridazine respectively. Blank ex-
periment was carried out simultaneously. The relative
fluorescence intensity of each sample solution for each
investigated drugs was accurately measured and plotted
against the final drug concentration (ng mL-1) to get the
calibration graphs.
Procedure for pharmaceutical formulations (tablets
and capsules)
A quantity of finely powdered twenty tablets or mixed
capsules contents equivalent to 100.0 mg of active com-
ponent was transferred to 50-mL volumetric flask, soni-
cated for about 10 minute with about 30 mL double
distilled water. The volume was made up with distilled
water, mixed well and filtered. The first portion of the
filtrate was discarded; twenty mL of the clear solution
was transferred quantitatively to a 125 mL separating
funnel. The contents of the funnel were rendered alka-
line with dropwise addition 33% w/v aqueous ammonia
solution, and the procedure was completed as described
under preparation of the standard solutions.
Procedure for spiked human plasma
5.0 mL of drug free human blood sample was taken
from three healthy volunteers into a heparinized tubes,
centrifuged at 3000 rpm for 30 minutes then 1.0 mL of
the drug free plasma (supernatant) was spiked with
1.0 mL of investigated drugs containing 5.0-45.0 μg mL-1
of fluoxetine and sertraline, 5.0- 55.0 μg mL-1 of
paroxeine, 10.0- 65.0 μg mL-1 of thioridazine and 10.0-
75.0 μg mL-1 of amineptine. 2.0 mL of acetonitrile was
added as precipitating agent for protein then centrifuged
at 4000 rpm for about 20 min. The supernatant was ren-
dered alkaline by adding 1.0 mL of 33% w/v aqueous
ammonia and then extract the librated free base three
times with 3 × 3 mL of chloroform. The combined
chloroformic extracts were filtered through anhydrous
sodium sulfate supported on Whitman filter paper. The














Figure 1 Fluorescence spectra of the produced CT-complex of
fluoxetine (450 ngml-1) with 1 × 10-3 M TCNQ where; A)
Excitation spectrum B) Emission spectrum, C) Excitation
spectrum of blank and D) Emission spectrum of blank.
Figure 3 Effect of temperature on the RFI of the reaction
product using TCNQ and 350 ng mL-1 of the studied drugs.
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were diluted to volume with chloroform. Aliquotes cov-
ering the working concentration range was transferred
into 10-mL volumetric flasks; then the general procedure
was followed. A blank value was determined by treating
the drug free blood sample in the same manner.Procedure for real human plasma
For fluoxetine, 20.0 mg was taken orally once daily by
three healthy human volanteers for 4 weeks. 5.0 mL of hu-
man blood sample was taken by using heperanized tube
after an average of 6 hrs following the last oral administra-
tion and centrifuged at 3000 rpm for 30 minute. 3.0 mL of
plasma obtained was treated with 2.0 mL of acetonitrile as
precipitating agent for protein then centrifuged at
4500 rpm for about 20 minute. The supernatant was ren-
dered alkaline by adding 1.0 mL of 33% w/v aqueous am-
monia followed by extraction with 3 × 3 mL of chloroform.
The combined extracts were diluted to volume with
chloroform; then the general procedure was followed.
For paroxetine, 40.0 mg was taken orally once daily
by three healthy human volanteers for 14 days. 10.0 mLFigure 2 Effect of reaction time on the RFI of the reaction
product using TCNQ and 350 ng mL-1 of the studied drugs.of human blood sample was taken by using heperanized
tube after an average of 12 hrs following the last oral ad-
ministration and centrifuged at 3000 rpm for 30 minute.
6.0 mL of plasma obtained was treated with 4.0 mL of
acetonitrile as precipitating agent for protein then
centrifuged at 4500 rpm for about 20 minute; then the
procedure was followed as described for fluoxetine
starting from “The supernatant was rendered alkaline
by. . .”.
For bupropion, 150.0 mg was taken orally every
12 hrs by three healthy human volanteers for 14 days.
5.0 mL of human blood sample was taken by using
heperanized tube after an average of 6 hrs following the
last oral administration; then the procedure was followed
as described for fluoxetine.
For sertraline, 50.0 mg was taken orally once daily by
three healthy human volanteers for 14 days. 5.0 mL of
human blood sample was taken by using heperanized
tube after an average of 12 hrs following the last oral ad-
ministration; then the procedure was followed as de-
scribed for fluoxetine.
For thioridazine, 100.0 mg was taken orally four
times daily by three healthy human volunteers for 7 days.
5.0 mL of human blood sample was taken by using
heperanized tube at 8 th day, 3 hrs after the last morning
oral administration; then the procedure was followed as
described for fluoxetine.Figure 4 Effect of 1 × 10-3 M TCNQ volume on its reaction with



















Fluoxetine TCNQ Charge transfere complex
Figure 5 The suggested reaction pathway between fluoxetine as representative example of the studied drugs with TCNQ.
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The aim of this work is to establish a simple, sensitive,
reliable, selective and cheap spectrofluorimetric method
for the analysis of investigated drugs in pure forms,
pharmaceutical formulations, spiked and real human
plasma. The developed method was based on reaction of
investigated drugs with 7,7,8,8-tetracyanoquinodimethane
(TCNQ) to form highly fluorescent product, measured
fluorometrically.
Fluorescence spectrum
Solutions of the studied drugs have very weak native fluor-
escence intensity, however in presence of TCNQ, the
fluorescence intensity increases substantially. The formed
CT complexes between the investigated drugs and TCNQ
were probably through the lone pair of electron donated
by the N atom in investigated drugs (n-donor) to TCNQ
(π-acceptor). The fluorescence intensity of the reaction
product was measured at 443, 447, 447, 450 and 458 nm
after excitation at 290, 291, 291, 295 and 301 nm for
fluoxetine, sertraline, paroxetine, amineptine and thiorida-
zine respectively. Figure 1 shows the fluorescence spectra
of the reaction product of fluoxetine as a representative
example of investigated drugs TCNQ.
Optimization of variables
The spectrofluorimetric properties of the fluorescent
product as well as the different experimental parameters
affecting the development and stability of the CT-complex
were carefully studied and optimized. Each factor was









Fluoxetine 50-450 −0.20 2.58
Sertraline 50-450 −2.18 2.82
Paroxetine 50-550 0.63 2.45
Thioridazine 100-650 −1.47 2.68
Amineptine 100-750 −0.43 2.37The studied factors include diluting solvent, reaction time,
temperature and concentration of the reagent.
In order to select the suitable solvent for CT-complex
formation, the reaction of TCNQ with studied drugs
was carried out in different solvents. The studied sol-
vents are chloroform, acetonitrile, ethanol, methanol
and 1,2-dichloroethane. It was found that chloroform
was considered to be the best solvent for the fluores-
cence development proved by the highest RFI observed
relative to other solvents.
The fluorescence intensity of the formed CT-complex
was monitored at different time intervals. It was found
that complete fluorescence developments were attained
after 40 minutes for fluoxetine, sertraline and paroxe-
tine; after 35 min for thioridazine and after 45 min
for amineptine (Figure 2). The fluorescence intensity
remained stable for at least 2 hours.
The effect of temperature on the formed charge transfer
complexes was studied in the range of 10 - 60°C. All the
formed complexes were stable up to 40°C. At temperature
higher than 40°C, the RFI decreases probably due to dis-
sociation of the complex. Thus, the determinations of stud-
ied drugs were carried out at 25 ± 5°C (Figure 3).
Different volumes of 1 × 10-3 M of TCNQ reagent were
used ranging from 0.2 to 1.4 mL. It was observed that the
relative fluorescence intensity (RFI) increases by increas-
ing volume of TCNQ and reaches its maximum values at
1 mL of 1 × 10-3 M of TCNQ after which no further
increase in RFI was observed. So 1 mL of 1 × 10-3 M
of TCNQ was chosen as an optimum concentration for











1.45 0.9995 5.35 17.85
1.36 0.9998 6.23 20.77
1.10 0.9997 6.68 22.26
0.71 0.9992 11.37 37.90
0.57 0.9990 12.48 41.61
Table 3 Evaluation of accuracy of the investigated analytical procedure at three concentration levels within the
specified range
Drug 50.0 ng mL-1 Recovery %a 250.0 ng mL-1 450.0 ng mL-1
Fluoxetine 100.94 ± 1.29 99.80 ± 0.51 100.41 ± 0.28
Sertraline 99.84 ± 1.69 98.91 ± 0.55 100.14 ± 0.30
50.0 ng mL-1 Recovery % a 250.0 ngmL-1 550.0 ngmL-1
Paroxetine 100.92 ± 1.28 100.09 ± 0.67 100.06 ± 0.31
100.0 ngmL-1 Recovery % a 350.0 ngmL-1 650.0 ngmL-1
Thioridazine 100.44 ± 1.57 101.31 ± 0.95 100.48 ± 0.41
100.0 ngmL-1 Recovery % a 450.0 ngmL-1 750.0 ngmL-1
Amineptine 100.14 ± 1.87 98.81 ± 0.72 100.47 ± 0.44
a Mean of Six replicate measurements.
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The stoichiometric of the reaction mechanism was stud-
ied adopting the job's method (Job 1964) of continuous
variation. The molar ratio of TCNQ to each of investi-
gated drugs was 1:1. The reaction pathway proposed in
Figure 5 is presented.
Validation of the proposed method
Concentration range (Topic Q2A 1994) was established
by confirming that the analytical procedure provided a
suitable degree of precision, accuracy and linearity when
applied to the sample containing amount of analyte
within or at the extreme of the specified range of the
analytical procedure (Topic Q2B 1996; The United
States Pharmacopoeia XXV and NF XX 2002). In this
work, concentration ranging from 50 to 450 ng mL-1
(for fluoxetine and sertraline), 50 to 550 ng mL-1 (for
paroxetine), 100 to 650 ng mL-1 (for thioridazine) and
100 to 750 ng mL-1 (for amineptine) were studied. The
whole set of experiments were carried out within this
range to ensure the validation of the proposed proced-
ure. Linear calibration graphs were obtained for all the
studied drugs by plotting the RFI of the studied drugs
versus the drug concentration (ng mL-1) within the spe-
cified range.
Linearity was indicated by high correlation coefficient
obtained. The correlation coefficients (r) of the formedTable 4 Statistical analysis of the results obtained using the p
spectrofluorimetric analysis of authentic samples using TCNQ
Drug % Recovery ± SD
Proposed methods Report
Fluoxetine 100.34 ± 0.89 99
Sertraline 99.61 ± 1.57 99
Paroxetine 99.29 ± 1.02 99
Thiridazine 100.32 ± 1.24 100
Amineptine 100.37 ± 1.04 100
bTabulated value at 95% confidence limit; F = 6.338 and t = 2.306.
#References (Darwish 2005; Mohamed et al. 2005, 2007).products were in the range 0.9990 to 0.9998 indicating
good linearity, as shown in Table 2.
Accuracy (The United States Pharmacopoeia XXV
and NF XX 2002) was checked at three concentration
levels within the specified range. Six replicate measure-
ments were recorded at each concentration level. The
results were expressed as percent recovery ± standard
deviation (Table 3). The obtained results show the close
agreement between the measured and true values.
Meanwhile, comparison of the obtained results from the
analysis of the drug products by the proposed procedure
with those obtained from the reported methods
(Darwish 2005; Mohamed et al. 2005, 2007) revealed
that their is no significant difference between them
with respect to accuracy as indicated by t- and F- tests
(Table 4).
Precision (The United States Pharmacopoeia XXV
and NF XX 2002) was checked at three concentration
levels, eight replicate measurements were recorded at
each concentration level; the results are summarized in
Table 5. The calculated relative standard deviations were
below 2.2% indicating excellent precision of the pro-
posed procedure at both levels of repeatability and inter-
mediate precision.
Limit of detection (Topic Q2A 1994) was calculated
based on standard deviation of response and the slope
of calibration curve (Topic Q2B 1996). The limitroposed procedures and reference method for
t-value b F-value b
ed method #
.95 ± 1.08 0.62 1.44
.67 ± 1.61 0.06 1.05
.38 ± 1.20 0.13 1.40
.39 ± 1.30 0.09 1.09
.57 ± 1.69 0.23 2.63
Table 5 Evaluation of precision of the proposed
spectrofluorimetric method for the determination of the
investigated drugs
Drug Conc. μg/ml Meanc S.D RSD
Fluoxetine 50 100.84 1.33 1.32
250 98.81 0.62 0.63
450 100.47 0.41 0.41
Sertraline 50 99.77 1.50 1.50
250 98.87 0.50 0.51
450 100.17 0.28 0.27
Paroxetine 50 100.71 1.32 1.31
250 100.14 0.69 0.69
550 100.08 0.28 0.28
Thioridazine 100 100.86 1.58 1.57
350 101.31 0.76 0.75
650 100.46 0.37 0.37
Amineptine 100 100.10 1.84 1.84
450 98.77 0.65 0.66
750 100.53 0.39 0.39
Cmean is average of eight determinations.
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Pharmacopoeia XXV and NF XX 2002):
LOD ¼ 3σ=S ð1Þ
Where σ is the standard deviation of intercept. S is the
slope of calibration curve.
The results are summarized in Table 2. The calculated
detection limits for all the studied drugs were less than
12.48 ng mL-1 indicating good sensitivity of the pro-
posed method.
Limit of quantitation (Topic Q2A 1994) was calcu-
lated based on standard deviation of intercept and slope
of calibration curve. In this method, the limit of quanti-
tation is expressed as (The United States Pharmacopoeia
XXV and NF XX 2002):




Starch 50 100.07 ± 0.61 99.19 ±
Lactose 50 98.21 ± 0.91 99.83 ±
Mg stearate 50 101.25 ± 0.54 98.24 ±
Gum acacia 50 99.25 ± 0.59 99.76
Talc 50 100.38 ± 1.58 100.18
dAverage of three determinations.The calculated quantitation limits for all the studied
drugs were all less than 41.61 ngmL-1, as shown in
Table 2, indicating good sensitivity of the proposed
method. So it can be applied for analysis of drug in bio-
logical fluids.
Specificity and interference
The specificity of the method was investigated by obser-
vation of any interference encountered from the com-
mon tablet excipients, such as talc, starch, gum acacia,
lactose and magnesium stearate. This study indicates
that the presence of these excipients did not interfere
with the proposed method as proved by the excellent re-
coveries obtained, as shown in Table 6.
Application to pharmaceutical dosage forms
The proposed method was applied for determination of
investigated drugs in commercial pharmaceutical dosage
forms. The results were statistically compared with those
of reported methods (Darwish 2005; Mohamed et al.
2005, 2007), in respect to accuracy and precision. The
obtained mean recovery values were 100.62-101.01 ±
0.66-1.39%, as shown in Table 7. According to t- and
F- tests, no significant difference was found between the
proposed and reported methods at 95% confidence level.
This indicates good level of precision and accuracy.
Application to spiked human plasma
The high sensitivity attained by the proposed method
allowed the determination of the studied drugs in spiked
human plasma. The concentrations of investigated CNS
drugs were computed from their corresponding regres-
sion equations. The obtained mean recovery values of
the obtained amount were 99.76-100.39 ± 1.33 - 1.99%
(Table 8).
Analysis of cited drugs in real human plasma
Fluoxetine is metabolized into its active metabolite
norfluoxetine (Lemberger et al. 1985). Norfluoxetine con-
centrations are approximately equal to those of the parent
drug during chronic therapy (Brunswick et al. 2002a).
After a fixed daily dose of fluoxetine (20.0 mg day-1), thepresence of some common excipients using the proposed
% Recovery d ± SD
line Paroxetine Thioridazine Amineptine
0.72 99.85 ± 0.87 100.80 ± 0.78 101.29 ± 0.79
0.63 98.78 ± 0.61 100.73 ± 0.71 98.12 ± 0.45
1.25 101.58 ± 1.61 99.86 ± 0.33 101.62 ± 1.07
±1.01 98.82 ± 0.86 100.28 ± 0.89 101.98 ± 0.49
±0.25 98.21 ± 0.67 99.70 ± 0.51 99.81 ± 0.34
Table 7 Statistical analysis of the results obtained using
the proposed spectrofluorimetric and reported methods








methods 8-10 ± SD
(n = 5)
Fluoxetine Neurazine
W tablets 100.94 ± 1.390 100.53 ± 1.46
t = 0.45 e F = 1.09 e
Sertraline Thiozine
W tablets 100.18 ± 1.15 100.13 ± 1.68
t = 0.06 F = 2.13
Paroxetine Stellasil
W tablets 100.01 ± 1.196 99.98 ± 0.95
t = 0.04 F = 1.59
Thioridazine Tryptizol
W tablets 100.62 ± 0.663 100.22 ± 1.07
t = 0.71 F = 2.59
Amineptine Survector
W capsules 100.14 ± 1.26 99.88 ± 1.59
t = 0.29 F = 1.59
eTabulated value at 95% confidence limit; F = 6.338 and t = 2.306.
Table 9 % Recoveries after application of the proposed
method for determination of investigated CNS drugs in
real human plasma sample
Drug Intraday assay Interday assay
% Recoveryinvivo % Recoveryinvivo
Fluoxetine
Mean ± SD 91.53 ± 5.11 86.28 ± 5.27
Sertraline
Mean ± SD 88.83 ± 5.38 85.50 ± 5.947
Paroxetine
Mean ± SD 76.76 ± 4.82 75.28 ± 7.94
Thioridazine
Mean ± SD 91.53 ± 5.11 92.26 ± 2.73
Amineptine
Mean ± SD 86.29 ± 6.44 87.41 ± 3.87
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blood continued to grow through the first few weeks of
treatment, and their steady concentration in the blood
is achieved only after four weeks (Pérez et al. 2001;
Brunswick et al. 2002b). Paroxetine is completely absorbed
after oral administration and metabolized in the




and (3S,4R)-3-hydroxymethyl- 4-(4-fluorophenyl) piperi-
dine (M3) (Hiemke & Hartter 2000). Steady-state plasma
paroxetine concentrations were achieved after approxi-
mately 10 days following 40-mg once daily dose
(Mandrioli et al. 2007). Thioridazine is mainly metabo-












Mean ± SD 99.68 ± 1.99 100.03 ± 1.92
fMean of three replicate measurements.plasma thioridazine concentrations were achieved after
approximately 7 days following four 100-mg doses per day
(Vanderheeren & Muusze 1977). Sertraline is mainly me-
tabolized into N-desmethylsertraline. Steady state plasma
concentration level for sertraline and its metabolite were
achieved after approximately one week of a 50-mg once-
daily dosing (Package Insert, Zolofi@, Pfizer Inc 1992;
Mandrioli et al. 2006). Amineptine is mainly metabolized
by beta-oxidation of the side chain, its principle metabolites
has the same structure as the parent compound except that
its side chain is reduced to five carbon atom (Lachatre et al.
1989). Steady state plasma level is achieved at 8 th day fol-
lowing two 100.0 mg doses per day (Rop Pok et al. 1990).
According to the reported metabolic pathway of all the
cited drugs; the proposed method can be used specifically
for determination of fluoxetine and sertraline only in pres-
ence of their metabolites in plasma because the metabolic












99.73 ± 1.73 99.76 ± 1.565 100.39 ± 1.33
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should not interfere upon application of the suggested
procedure, while for thioridazine, paroxetine and
amineptine, their metabolites can interfere with the de-
termination of the parent drugs because they contain
the same function group (secondary or tertiary amine
moiety) as well.
So % recovery of fluoxetine and sertraline in plasma
were calculated by using the following equation




% Recovery in vivo is % recovery for drug in real human
sample.
Concentration found is concentration of the drug
founded in real human sample.
Concentration taken is concentration of the drug
reported in real human sample.
While % recovery of thioridazine, paroxetine and
amineptine and their metabolites in plasma were
calculated by using the same equation
Where,
% Recovery in vivo is % recovery for drug and their
metabolites in real human sample.
Concentration found is concentration of the drug and
their metabolites founded in real human sample.
Concentration taken is reported concentration of the
drug and their metabolites in real human sample.
% Recoveries after application of the proposed method
for determination of investigated CNS drugs in real
human plasma sample by intra and inter day assay are
shown in Table 9.
Conclusion
The proposed spectrofluorimetric method has the ad-
vantage of being simple, highly sensitive and low cost
method for determination of the investigated antidepres-
sant drugs in pure forms, pharmaceutical formulations,
without any interference from common excipients
present and with minimum detection limits. Further-
more the proposed method was successfully applied for
analysis of the cited drugs in spiked and real human
plasma. Therefore, the developed method can be con-
sidered as suitable for routine analysis of investigated
antidepressant drugs in quality control and clinical la-
boratories. Also it is suitable for selective determinationof fluoxetine and sertraline only without their metabo-
lites in human plasma.Competing interests
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